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Approximately one-third of medulloblastoma cases are associated with genetic lesions of Hedgehog
(Hh) signaling pathway components. In this issue of Developmental Cell, Mille et al. (2014) show that the
Hh coreceptor Boc functions specifically in the progression of early- to advanced-stage medulloblastoma
by promoting Cyclin D1-dependent DNA damage and genomic instability.Medulloblastoma (MB), a neuroectoder-
mal malignancy affecting the cerebellum,
is themost frequent pediatric brain tumor.
While current treatment options have
significantly improved overall survival
rates, young patients often suffer perma-
nent functional impairments due to the
impact of nonspecific therapies on the
developing brain. Molecularly, MB can
be classified into four major subtypes:
one group characterized by a WNT-
induced gene signature, another group
showing Hedgehog (Hh) pathway activa-
tion (SHH group), and groups 3 and 4
(Northcott et al., 2012). The SHH group
accounts for approximately 30%of all pa-
tients and is further subdivided according
to the specific Hh pathway mutation pre-
sent (Kool et al., 2014). Ptch1, the primary
Hh-ligand binding receptor, is the most
frequently genetically altered pathway
component and represses activation of
downstream signaling in the absence of
ligand. Ptch1 interacts with at least one
coreceptor, such as Cdon (cell-adhe-
sion-molecule-related/downregulated by
oncogenes), Boc (Brother of Cdon), or
Gas1 (Growth-arrest-specific 1), to form
a functional receptor complex (Allen
et al., 2011; Izzi et al., 2011). While the
importance of Ptch1 inactivation is undis-
puted, potential roles for Cdon or Boc in
MB tumorigenesis are unclear.
Now in Developmental Cell, Mille and
colleagues shed light on the role of the
Boc coreceptor in MB (Mille et al., 2014).
The authors found thatBocmRNA is over-
expressed preferentially in the SHH group
of human MB tumors, while its homolog
Cdon is not. Moreover, about one-third
of the tumors in the SHH group showeda gain of human chromosome 3q13.2,
which harbors the BOC gene; increased
Boc expression was also observed in
two different SHH group MB mouse
models. Functionally, overexpression of
Boc in isolated murine cerebellar granule
neuron precursor (CGNP) cells, which
are cells of origin in SHH-group MBs, in-
creased their proliferation and enhanced
Hh signaling, consistent with previous
studies in other cell types (Tenzen et al.,
2006; Figure 1). Importantly, overex-
pression of Boc alone was insufficient to
stimulate pathway activity, suggesting
that the costimulatory role of Boc in the
Hh pathway is ligand dependent.
The authors then bred Ptch1+/mice, a
well-characterized model of MB, onto a
Boc null genetic background and found
that homozygous Boc deletion signifi-
cantly reduced the incidence of high-
grade MB tumors. Detailed histological
analyses revealed that Boc was ex-
pressed in CGNPs at very early stages
of tumorigenesis. Significantly, genetic
abrogation of Boc expression did not
decrease the incidence of early tumor le-
sions, but rather selectively reduced tu-
mor size. These findings argue that Boc
does not have an important role in MB tu-
mor initiation, but rather promotes tumor
growth and progression. Consistently,
the authors found reduced expression of
proliferation-promoting genes, including
Cyclin D1 or N-myc, in MB tumors from
Boc null animals.
Mille et al. then asked whether MB pro-
gression resulting from increased BOC
expressionmight be due to factors in addi-
tion to increased cellular proliferation. The
authors hypothesized that the Boc-medi-Developmental Cellated increases in Cyclin D1 and N-myc
levels might evoke oncogene-induced
replicative stress in early MB cells, in
which oncogenic activation leads to prolif-
eration-associated DNA damage during
replication (Aggarwal et al., 2007). To test
this hypothesis, the authors treated wild-
type and Boc-deficient CGNPs with Shh,
and levels of DNA damage were subse-
quently determined. Strikingly, obvious
signs of DNA damage were only observed
in wild-type cells and not in Boc-deficient
cells. Moreover, Cyclin D1 was required
for this effect, as genetic ablation ofCyclin
D1 blunted the effects of Shh on DNA
fragmentation in vitro. Because DNA dam-
age was not observed in noncycling cells
(irrespective of Boc status), the authors
concluded that elevated Cyclin D1 levels
led to proliferation-associated replicative
stress. The effects of Boc are specific to
the canonical Hh signaling pathway, as
Boc deletion has no effect when Hh sig-
naling is artificially activated downstream
of it.
Loss of Ptch1 heterozygosity (LOH),
leading to the subsequent hyperactivation
of Hh pathway signaling, plays a key role
in fostering the progression from prema-
lignant to advanced MB (Oliver et al.,
2005; Pazzaglia et al., 2006). Because
Shh induces Boc/CyclinD1-mediated
DNA damage, Mille and colleagues asked
whether this DNA damage affects the
stability of the Ptch1 locus. Indeed,
Ptch1 LOH was observed in all advanced
MBs in the Ptch1+/ mouse model with
wild-type Boc expression. In contrast,
about 10% of advanced Boc null MB
tumors retained the wild-typePtch1 allele,
indicating that Boc protects against31, October 13, 2014 ª2014 Elsevier Inc. 1
Figure 1. Increased Boc Expression Promotes Hedgehog-Driven Medulloblastoma
Progression
Initiation of Hh signaling, e.g., due to an inactivating mutation in one allele of Ptch1, results in elevated
expression of the Hh target gene Boc (step 1). Boc expression, in turn, amplifies Hh signaling strength
(step 2), leading to strong upregulation of Cyclin D1 (step 3). Subsequently, the oncogene Cyclin D1 in-
duces cell proliferation and DNA damage (step 4) in early MB cells. Critically, this Cyclin D1-induced
DNA damage triggers genetic inactivation of the second Ptch1 allele (Ptch1 LOH, step 5). Complete
loss of Ptch1 function strongly derepresses Hh signaling and allows the tumor to progress to advanced
stages (step 6). At this point, the tumor is no longer dependent on the presence of Boc. Of note, this sce-
nario depicts MB induced by activation of Hh signaling at the level of Ptch1 and does not apply to MB
induced by alternative routes of Hh pathway activation.
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age at the Ptch1 locus. However, Boc/
tumors that have lost the second copy
of Ptch1 show strong signals of Hh
pathway upregulation, including upregu-
latedCyclin D1 orN-myc expression inde-
pendent of the Boc-Ptch1 axis. Consis-
tently, survival of animals in which MB
was induced by oncogenic activation of
Smoothened (which lies downstream of
Boc and Ptch1) is unaffected by the Boc
genotype.
Thus, Mille et al. describe a surprising
picture in which Boc levels determine
the likelihood of complete Ptch1 inactiva-
tion and thus the probability that a prema-2 Developmental Cell 31, October 13, 2014 ªlignant lesion will develop into advanced
lethal MB (Figure 1). The findings in this
study raise questions for future investiga-
tion: Are increased levels of BOC protein
in MB correlated to the presence of
PTCH1 mutations, and are they of a
magnitude sufficient to induce DNA dam-
age in the setting of human MB? Do addi-
tional effectors concomitantly induced
with Cyclin D1, such as N-myc, also play
a role in Shh-stimulated DNA damage?
Additionally, some studies have sug-
gested that increased Hh signaling may
paradoxically enhance expression of
DNA repair genes, prompting the need
for further studies to delineate links be-2014 Elsevier Inc.tween Hh signaling and genomic integrity.
Clearly, the present study advances our
understanding of the natural history of
MB development and suggests BOC as
a potential target for intervention in pa-
tients with germline PTCH1 mutations.
At a broader level, these data suggest
that increased expression of accessory
receptor proteins may enhance onco-
genic signaling and tumorigenesis in a
stage-specific manner, adding a layer of
complexity to the functional dissection of
genetic and transcriptional changes pre-
sent in human tumors.REFERENCES
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